Saturday July 21, 2018

Effective Treatment to Protect Cancer Patients From Blood Clots

Taking oral drugs daily can be an effective treatment for nearly 10 million cancer patients worldwide suffering from a deadly blood clot condition, results from a clinical trial have showed.

0
//
36
For the
Blood cells, pixabay
Republish
Reprint

Taking oral drugs daily can be an effective treatment for nearly 10 million cancer patients worldwide suffering from a deadly blood clot condition, results from a clinical trial have shown.

People with cancer have an increased risk of developing blood clots, with roughly one in five experiencing venous thromboembolism (VTE) — either a blood clot in a deep vein or a condition in which one or more arteries in the lungs become blocked by a blood clot.

The results from the clinical trial called “select-d” suggested that prescribing the oral drug rivaroxaban significantly reduced VTE recurrence among patients with cancer.

“Clinicians were already adopting the oral drug into practice for non-cancer patients and now they have data from this study to indicate that this form of treatment is an alternative option for many cancer patients who have a clot,” said lead author Annie Young, Professor at the University of Warwick in Britain.

Although there are many causes and risk factors for VTE, cancer patients are particularly at risk due to a combination of factors such as immobility, pancreatic and gastric tumours as well as chemotherapy, the researcher said.

The reason for increased bleeding is not known. It may be because rivaroxaban is more 'potent', the paper published in the Journal of Clinical Oncology said. (IANS)
Representational image, pixabay

For the “select-d” trial, researchers enrolled 406 patients who had cancer and VTE; most (69 per cent) were receiving cancer treatment (typically chemotherapy) at the time of their VTE.

Half were randomly assigned to receive low-molecular-weight heparin (dalteparin) and half were given the oral drug rivaroxaban. After six months of treatment, the VTE recurrence rate was four per cent among those taking the tablet and 11 per cent in those receiving dalteparin.

The results for secondary outcomes were mixed, the researcher said.

In patients receiving rivaroxaban, there were around the same percentage of major bleeding events (6 per cent) as those receiving dalteparin (4 per cent) but a marked and significant increase in clinically relevant non-major bleeds (13 per cent) with rivaroxaban compared to those having low molecular weight heparin (4 per cent).

Also Read: Drug Used For Osteoporosis May Help in Reducing Heart Attack Risk

The reason for increased bleeding is not known. It may be because rivaroxaban is more ‘potent’, the paper published in the Journal of Clinical Oncology said. (IANS)

Click here for reuse options!
Copyright 2018 NewsGram

Next Story

Diabetic Women at Greater Risk of Developing Cancer Than Men, According to a New Study

Overall, it was calculated that women with diabetes were six per cent more likely to develop any form of cancer than men with diabetes

0
The researchers found that women with diabetes were 27 per cent more likely to develop cancer than women without diabetes but for men the risk was 19 per cent higher.
The researchers found that women with diabetes were 27 per cent more likely to develop cancer than women without diabetes but for men the risk was 19 per cent higher. Pixabay

Women suffering from diabetes may be at a higher risk of developing cancer than men, a new study has found.

The findings suggested that among the study participants, women with diabetes (Type 1 and Type 2) were at higher risks for developing kidney cancer (11 per cent), oral cancer (13 per cent), stomach cancer (14 per cent) and leukaemia (15 per cent) compared to men with the similar condition.

Diabetes affects more than 415 million people worldwide, with five million deaths every year.

According to the researchers, it is believed that heightened blood glucose may have cancer-causing effects by leading to DNA damage.

“The link between diabetes and the risk of developing cancer is now firmly established,” said lead author Toshiaki Ohkuma from The George Institute for Global Health in Australia.

They also found that diabetes was a risk factor for the majority of cancers of specific parts of the body for both men and women.
They also found that diabetes was a risk factor for the majority of cancers of specific parts of the body for both men and women. Pixabay

“The number of people with diabetes has doubled globally in the last 30 years but we still have much to learn about the condition,” Ohkuma added.

For the study, published in the journal Diabetologia, the researchers examined data on all-site cancer events (incident or fatal only) from 121 cohorts that included 19,239,302 individuals.

The researchers found that women with diabetes were 27 per cent more likely to develop cancer than women without diabetes but for men the risk was 19 per cent higher.

Also Read: Eating Dinner Early May Lower Risk of Breast, Prostate Cancer

They also found that diabetes was a risk factor for the majority of cancers of specific parts of the body for both men and women.

Overall, it was calculated that women with diabetes were six per cent more likely to develop any form of cancer than men with diabetes.

“It’s vital that we undertake more research into discovering what is driving this, and for both people with diabetes and the medical community to be aware of the heightened cancer risk for women and men with diabetes,” Ohkuma noted. (IANS)